Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEN-STEM dendritic cell immunotherapy trial in glioblastoma
2024-518663-35-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mDCt survivin, mature dendritic cells transfected with human telomerase reverse transcriptase and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Progression-free survival, Corrected progression timing after overall survival follow-up and 1 more. Planned start Apr 2018; status: authorised.
02
Drugs
mDCt survivinmature dendritic cells transfected with human telomerase reverse transcriptasetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-518663-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518663-35-00.